Harrington, Patrick http://orcid.org/0000-0001-5704-466X
Doores, Katie J.
Saunders, Jamie http://orcid.org/0000-0002-8650-5362
de Lord, Marc
Saha, Chandan
Lechmere, Thomas http://orcid.org/0000-0002-9656-6038
Khan, Hataf http://orcid.org/0000-0003-1128-0266
Lam, Ho Pui Jeff http://orcid.org/0000-0002-5732-2882
Reilly, Amy O’
Woodley, Claire
Asirvatham, Susan
Dillon, Richard
Curto-Garcia, Natalia
Sullivan, Jennifer O’
Kordasti, Shahram
Raj, Kavita
Malim, Michael H. http://orcid.org/0000-0002-7699-2064
Radia, Deepti
McLornan, Donal http://orcid.org/0000-0003-1224-091X
Harrison, Claire
de Lavallade, Hugues http://orcid.org/0000-0002-4988-2564
Article History
Received: 28 January 2022
Revised: 16 March 2022
Accepted: 17 March 2022
First Online: 22 April 2022
Competing interests
: PH reports research funding from Bristol Myers Squibb and speaker’s fees from Incyte. DM has received speaker fees and advisory boards Novartis, Celgene and Jazz pharmaceuticals. CH has received speaker fees from Novartis, Jannsen, CTI, Celgene, Medscape and has served on the Advisory Board for Incyte, CTI, Sierra Oncology, Novartis, Celgene, Roche, AOP pharma, Geron and Astra Zenica. HdL has received research grants and honoraria from Incyte and honoraria from Novartis and Pfizer.